Assertio Holdings, Inc. (NASDAQ:ASRT - Free Report) - Equities research analysts at Sidoti Csr issued their Q2 2024 earnings estimates for Assertio in a note issued to investors on Tuesday, May 7th. Sidoti Csr analyst J. Sidoti anticipates that the company will post earnings of ($0.02) per share for the quarter. The consensus estimate for Assertio's current full-year earnings is ($0.04) per share. Sidoti Csr also issued estimates for Assertio's Q3 2024 earnings at ($0.03) EPS, Q4 2024 earnings at ($0.03) EPS and FY2024 earnings at ($0.13) EPS.
Assertio (NASDAQ:ASRT - Get Free Report) last issued its quarterly earnings data on Monday, March 11th. The company reported $0.08 earnings per share for the quarter. The business had revenue of $32.99 million during the quarter, compared to the consensus estimate of $31.42 million. Assertio had a negative net margin of 218.28% and a positive return on equity of 6.30%.
Separately, StockNews.com upgraded shares of Assertio from a "hold" rating to a "buy" rating in a research report on Tuesday.
Check Out Our Latest Stock Report on Assertio
Assertio Stock Performance
ASRT stock traded down $0.09 on Friday, hitting $0.96. The company's stock had a trading volume of 1,421,566 shares, compared to its average volume of 1,043,350. The firm has a 50 day moving average of $0.94 and a two-hundred day moving average of $1.08. Assertio has a 1 year low of $0.73 and a 1 year high of $8.01. The stock has a market cap of $91.32 million, a price-to-earnings ratio of -0.27 and a beta of 1.00. The company has a current ratio of 1.83, a quick ratio of 1.43 and a debt-to-equity ratio of 0.28.
Hedge Funds Weigh In On Assertio
A number of institutional investors and hedge funds have recently made changes to their positions in ASRT. Principal Financial Group Inc. acquired a new position in shares of Assertio during the 3rd quarter worth $32,000. Strs Ohio acquired a new position in shares of Assertio during the 3rd quarter worth $33,000. Barclays PLC grew its stake in shares of Assertio by 32.1% during the 3rd quarter. Barclays PLC now owns 22,990 shares of the company's stock worth $59,000 after purchasing an additional 5,588 shares during the period. SG Americas Securities LLC grew its stake in Assertio by 45.4% in the 4th quarter. SG Americas Securities LLC now owns 55,769 shares of the company's stock valued at $60,000 after acquiring an additional 17,417 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System grew its stake in Assertio by 61.9% in the 3rd quarter. State Board of Administration of Florida Retirement System now owns 25,370 shares of the company's stock valued at $65,000 after acquiring an additional 9,700 shares during the last quarter. 48.96% of the stock is owned by institutional investors and hedge funds.
About Assertio
(
Get Free Report)
Assertio Holdings, Inc, a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis.
Featured Articles
Before you consider Assertio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Assertio wasn't on the list.
While Assertio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
